Andreas Kogelnik

Source: www.openmedicinefoundation.org

Andreas M. Kogelnik, ("Andy") MD, PhD., is an Internal Medicine and Infectious Diseases specialist, the director of the Open Medicine Institute, Mountain View, California, USA, and a member of the Scientific Advisory Board for the Open Medicine Foundation, Agoura Hills, CA. His interests are in the bioinformatics and genomic revolution in medicine and is committed to the study of and treatment of ME/CFS and other chronic illnesses.

Education

• MD from Emory University
• PhD in bioengineering from Georgia Tech
• Residency in Internal Medicine at Stanford University
• Fellowship in Infectious Diseases at Stanford University

Research publications on ME/CFS

• 2017, Multi-Site Clinical Assessment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (MCAM): Design and Implementation of a Prospective/Retrospective Rolling Cohort Study

  "Abstract - In the Multi-Site Clinical Assessment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (MCAM), we relied on expert clinician diagnoses to enroll patients from 7 specialty clinics in the United States in order to perform a systematic collection of data on measures of myalgic encephalomyelitis (ME)/chronic fatigue syndrome (CFS). Healthy persons and those with other illnesses that share some features with ME/CFS were enrolled in comparison groups. The major objectives were to: 1) use standardized questionnaires to measure illness domains of ME/CFS and to evaluate patient heterogeneity overall and between clinics; 2) describe the course of illness, identify the measures that best correlate with meaningful clinical differences, and assess the performances of questionnaires as patient/person-reported outcome measures; 3) describe prescribed medications, orders for laboratory and other tests, and management tools used by expert clinicians to care for persons with ME/CFS; 4) collect biospecimens for future hypothesis testing and for evaluation of morning cortisol profiles; and 5) identify measures that best distinguish persons with ME/CFS from those in the comparison groups and detect subgroups of persons with ME/CFS who may have different underlying causes. Enrollment began in 2012 and is planned to continue in multiple stages through 2017. We present the MCAM methods in detail, along with an initial description of the 471 patients with ME/CFS who were enrolled in stage 1."

• 2013, Randomized clinical trial to evaluate the efficacy and safety of valganciclovir in a subset of patients with chronic fatigue syndrome.
• 2011, No evidence of murine-like gammaretroviruses in CFS patients previously identified as XMRV-infected.
• 2006, Use of valganciclovir in patients with elevated antibody titers against Human Herpesvirus-6 (HHV-6) and Epstein-Barr Virus (EBV) who were experiencing central nervous system dysfunction including long-standing fatigue.

Articles

• 2014, Comments on Progressive Research Year of 2014

Talks and Interviews

• 2014, YouTube - What Works For Chronic Fatigue Syndrome
• 2014, 9th Invest in ME International ME Conference 2014 - No title of talk given

• 2014 Conference DVD

• 2014, ME/CFS Alert Episode 56: Dr. Andreas Kogelnik on the "Real Thrust" of ME/CFS Research
• 2014, ME/CFS Alert Episode 55: Interview with Dr. Andreas Kogelnik
• 17 Feb 2014, Dr. Andreas Kogelnik and Llewellyn King on Sirius XM Radio POTUS Channel 124
• 23 Jan 2014, Dr. Andreas Kogelnik, Ryan Prior and Llewellyn King appeared on “The Jim Bohannon Show”
• 2013, 8th Invest in ME International ME Conference Keynote Speaker: Strategies for ME Research and Collaboration

• 2013 Conference DVD

• 2012, ME/CFS Alert Episode 23:

The Open Medicine Institute, Part 1,

The Open Medicine Institute, Part 2,

The Open Medicine Institute, Part 3

• 2012, ME/CFS Alert Episode 22:

Interview with Dr. Andreas Kogelnik, Part 1

Interview with Dr. Andreas Kogelnik, Part 2

• 2012, 7th Invest in ME International ME Conference - Strategies for ME Research and Collaboration

• 2012 Conference DVD

• May 2011 - Keynote Speaker at the 6th Invest in ME International ME Conference - Speech Title: Strategies for ME Research and Collaboration

• 2011 Conference DVD

chronic illness any long-term illness, regardless of the severity. Chronic illnesses are typically incurable, requiring long-term management.

myalgic encephalomyelitis (M.E.) - A disease often marked by neurological symptoms, but fatigue is sometimes a symptom as well. Some diagnostic criteria distinguish it from chronic fatigue syndrome, while other diagnostic criteria consider it to be a synonym for chronic fatigue syndrome. A defining characteristic of ME is post-exertional malaise (PEM), or post-exertional neuroimmune exhaustion (PENE), which is a notable exacerbation of symptoms brought on by small exertions. PEM can last for days or weeks. Symptoms can include cognitive impairments, muscle pain (myalgia), trouble remaining upright (orthostatic intolerance), sleep abnormalities, and gastro-intestinal impairments, among others. An estimated 25% of those suffering from ME are housebound or bedbound. The World Health Organization (WHO) classifies ME as a neurological disease.

antibodies Antibody/immunoglobulin refers to any of a large number of specific proteins produced by B cells that act against an antigen in an immune response.

central nervous system (CNS) - One of the two parts of the human nervous system, the other part being the peripheral nervous system. The central nervous system consists of the brain and spinal cord, while the peripheral nervous system consists of nerves that travel from the central nervous system into the various organs and tissues of the body.